Findings

What do systematic reviews say?

24 questions · 28 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 12 · 42.9%GRADE not reported 13 · 46.4%Very low 3 · 10.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Bethanechol vs placebo

Rate of spontaneous voiding recovery 1 week after surgery

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bethanechol vs placebo

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bethanechol vs placebo

Time after surgery to post‐void residual volume of urine ≤ 50 mL (days)

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bethanechol vs placebo

Adverse events

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bethanechol vs placebo

Post‐void residual urine volume (mL) at 1 month after surgery

1 finding from 1 review

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Very low

Bethanechol vs placebo

Urinary tract infection

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bethanechol vs placebo

Subjective urinary symptoms

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bethanechol vs Artificial saliva

Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol showed no clear difference in xerostomia (dry mouth, yes/no) compared with artificial saliva; GRADE not reported.

2 findings from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
8 to 40 weeks postRT
RR 0.56 [0.30, 1.05]
1 study · 30 participants
GRADE not reported
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
RR 0.63 [0.30, 1.29]
1 study · 36 participants
GRADE not reported

Bethanechol vs Artificial saliva

Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with artificial saliva; GRADE not reported.

2 findings from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
MD 0.12 [0.01, 0.23]
1 study · 36 participants
GRADE not reported
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
8 to 40 weeks postRT
MD 0.07 [-0.02, 0.16]
1 study · 33 participants
GRADE not reported

Bethanechol vs Artificial saliva

Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol showed no clear difference in overall survival compared with artificial saliva; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
40 weeks postRT
RR 1.59 [0.43, 5.84]
1 study · 43 participants
GRADE not reported

Bethanechol vs placebo

Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No survival data were reported.
0 studies
No studies found

Bethanechol vs placebo

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on either quality of life or other oral related symptoms were reported.
0 studies
No studies found

Bethanechol vs Artificial saliva

Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol led to higher salivary flow rate (stimulated, ml/min) compared with artificial saliva; GRADE not reported.

2 findings from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
8 to 40 weeks postRT
MD 0.21 [0.01, 0.41]
1 study · 29 participants
GRADE not reported
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
MD 0.13 [-0.03, 0.29]
1 study · 32 participants
GRADE not reported

Bethanechol vs placebo

Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No statistical difference between groups in bethanechol-related toxicity; no patient experienced severe (grade 3) toxicity (Jaguar 2015)
1 study
GRADE not reported

Bethanechol vs placebo

Xerostomia (grade >= 2, 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol led to lower xerostomia (grade >= 2, 0-3 scale) compared with placebo; GRADE not reported.

2 findings from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
RR 0.43 [0.28, 0.66]
1 study · 84 participants
GRADE not reported
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Up to and including 3 months postRT
RR 0.81 [0.65, 1.01]
1 study · 84 participants
GRADE not reported

Bethanechol vs placebo

Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol showed no clear difference in salivary flow rate (stimulated, ml/min) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
2 months postRT
MD 0.15 [-0.03, 0.33]
1 study · 97 participants
GRADE not reported

Bethanechol vs placebo

Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
2 months postRT
MD 0.19 [0.06, 0.32]
1 study · 97 participants
GRADE not reported

Bethanechol vs Artificial saliva

Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Low rates of adverse effects (watering eyes, nervousness, frequent urination, sweating, warm face, cramps, diarrhoea, nausea) with insufficient evidence of any differences (Jham 2007)
1 study
GRADE not reported

Bethanechol vs Artificial saliva

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on either quality of life or other oral related symptoms were reported.
0 studies
No studies found

Bethanechol vs placebo

Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
short-term (up to 3 months)
SoF4: No included studies reported change in feeling of dryness.
0 studies
No studies found